

FORM PTO-1.149 (REV. 7-80)	ATTY. DOCKET NO. KIR96-01	SERIAL NO. 08/602,272
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		APPLICANTS: Michael J. Elliott, Ravinder N. Maini and Marc Feldmann
FILING DATE February 16, 1996		GROUP

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	AR	Elliott, M. J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α ," <i>Arthritis & Rheumatism</i> , 36(12): 1681-1690 (1993).
MAS	AS	Elliott, M. J., et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>The Lancet</i> , 344: 1105-1110 (1994).
MAS	AT	Wolfe, F., et al., "The Mortality of Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , 37(4): 481-494 (1994).
MAS	AU	Meade, T.W., "Fibrinogen in ischaemic heart disease," <i>European Heart J.</i> , 16(Suppl. A): 31-35 (1995).
MAS	AV	Brown, A.S., and Martin, J.F., "The megakaryocyte platelet system and vascular disease," <i>European J. of Clinical Investigation</i> , 24(Suppl. 1): 9-15 (1994).

EXAMINER

May A. John

DATE CONSIDERED

ERED
11/15/96